Viking Therapeutics (VKTX) announced that results from the company’s Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with ...
Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...
Analysts Predict a $102 Target for Viking Therapeutics Inc (VKTX) Stock—What Could Drive It There?
On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback